Table 4. Immunohistochemical analysis of CDO1 in esophageal cancer tissue microarray with normal tissue controls (ES804).
Grade | CDO1 (+) | % | P value | ||
a Normal | Total | 30/30 | 100 | ||
Normal | 10/10 | 100 | |||
Chronic esophagitis | 10/10 | 100 | |||
Hyperplasia | 10/10 | 100 | |||
Malignant | Total | 14/49 | 28.6 | ||
Adenocarcinoma | Subtotal | 4/20 | 20.0 | <0.001 * | |
II | 2/10 | 20.0 | |||
II–III, III | 2/8 | 25.0 | |||
Adenosquamous carcinoma | 0/1 | 0 | |||
Basaloid squamous cell carcinoma | 0/1 | 0 | |||
Squamous cell carcinoma | Subtotal | 9/20 | 45.0 | <0.001 * | |
I | 7/11 | 63.6 | |||
I–II, II | 1/5 | 20.0 | |||
III | 1/4 | 25.0 | |||
Metastatic cancer | Subtotal | 1/9 | 11.1 | <0.001 * | |
Metastatic adenocarcinoma | 0/3 | 0 | |||
Metastatic squamous cell carcinoma | 1/6 | 16.7 |
Expression level was indicated as −, absent or faint expression; +, moderate expression; ++, expression; +++, strong expression.
CDO1 positivity (+) was counted in samples with over moderate expression.
P values from Fisher’s exact test performed in normal vs. adenocarcinoma, squamous cell carcinoma, or metastatic cancer.
P<0.05 considered significant.
Non-malignant normal esophagus tissue and cancer adjacent normal esophagus tissue.